Combination of Linear Accelerator–Based Intensity-Modulated Total Marrow Irradiation and Myeloablative Fludarabine/Busulfan: A Phase I Study

Authors:

Abstract
No abstract available
Funding Information
  • Otsuka Pharmaceuticals
  • Varian Medical Systems Inc.

This publication has 44 references indexed in Scilit: